Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Huang R, Guo H, Chen J, Zhai T, Chen J, Lin K, et al. Intratreatment tumor volume change during definitive chemoradiotherapy is predictive for treatment outcome of patients with esophageal carcinoma. Cancer Manag Res. 2020;12: 7331–7339.
2. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randominsed phase II/III trial. Lancet. 2019;393(10184):1948-1957.
3. Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: Correlation with histopathology results. Am J Clin Oncol Cancer Clin Trials. 2007;30(4):377-88.
4. Beukinga RJ, Hulshoff JB, Van Dijk L V., Muijs CT, Burgerhof JGM, Kats-Ugurlu G, et al. Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment 18F-FDG PET/CT imaging. J Nucl Med. 2017;58(5):723-729.
5. Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2013;258(1):66-76.